Pro Share Advisors LLC Paratek Pharmaceuticals, Inc. Transaction History

Pro Share Advisors LLC

$39.7 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	SELL	$1.73 - $3.09 $24,868 - $44,418	-14,375 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$2.94 - $4.77 $9,946 - $16,136	-3,383 Reduced 19.05%	14,375 $43,000
Q4 2021 Feb 08, 2022	BUY	$4.07 - $5.3 $5,022 - $6,540	1,234 Added 7.47%	17,758 $80,000
Q3 2021 Nov 12, 2021	SELL	$4.7 - $7.24 $17,784 - $27,396	-3,784 Reduced 18.63%	16,524 $80,000
Q2 2021 Aug 13, 2021	BUY	$6.81 - $10.93 $15,914 - $25,543	2,337 Added 13.0%	20,308 $139,000
Q1 2021 May 14, 2021	BUY	$6.14 - $8.31 $7,760 - $10,503	1,264 Added 7.57%	17,971 $127,000
Q4 2020 Feb 09, 2021	BUY	$4.58 - $7.14 $76,518 - $119,287	16,707 New	16,707 $105,000
Q4 2019 Feb 12, 2020	SELL	$2.93 - $4.5 $36,490 - $56,043	-12,454 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$3.08 - $5.76 $1,281 - $2,396	-416 Reduced 3.23%	12,454 $54,000
Q2 2019 Aug 13, 2019	SELL	$3.47 - $6.32 $5,368 - $9,777	-1,547 Reduced 10.73%	12,870 $51,000
Q1 2019 May 15, 2019	BUY	$5.36 - $7.24 $1,098 - $1,484	205 Added 1.44%	14,417 $77,000
Q4 2018 Feb 14, 2019	SELL	$4.8 - $11.6 $12,379 - $29,916	-2,579 Reduced 15.36%	14,212 $73,000
Q3 2018 Nov 14, 2018	SELL	$9.05 - $10.95 $5,728 - $6,931	-633 Reduced 3.63%	16,791 $163,000
Q2 2018 Aug 13, 2018	SELL	$10.2 - $13.9 $4,416 - $6,018	-433 Reduced 2.42%	17,424 $178,000
Q1 2018 May 14, 2018	SELL	$12.65 - $18.85 $9,259 - $13,798	-732 Reduced 3.94%	17,857 $232,000
Q4 2017 Feb 14, 2018	BUY	$17.45 - $25.6 $22,946 - $33,664	1,315 Added 7.61%	18,589 $333,000
Q3 2017 Nov 13, 2017	BUY	$18.9 - $28.2 $20,468 - $30,540	1,083 Added 6.69%	17,274 $434,000
Q2 2017 Aug 11, 2017	BUY	N/A	16,191	16,191 $390,000

Others Institutions Holding PRTK

# of Institutions

Shares Held

1.54M

Call Options Held

Put Options Held

View Full List

About Paratek Pharmaceuticals, Inc.

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

More about PRTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account